CCL2 blocked the cell cycle entry of normal HSPCs but not CML progenitor cells, whereas TGF-β inhibited cell cycle entry of both normal HSPCs and CML LSCs [97]. The gene discussed is TGFB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.